Qtrilmet recommended for approval in EU by CHMP
23 September 2019 07:00 BST Qtrilmet recommended for approval in EU by CHMP for the treatment of type-2 diabetes AstraZeneca today announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the European Union for the treatment of adults with type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on data from five Phase III trials which evaluated combinations of Forxiga(dapagliflozin) and